All In Biotech

Drug Trial Radar · NCT03241550

A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Oct 2, 2017

Primary completion

Jul 5, 2019

Study completion Jul 5, 2019

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Basilea Pharmaceutica International Ltd
First posted
Aug 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of intravenous (IV) and oral isavuconazonium sulfate administered daily in pediatric patients. The PK data will be utilized to establish a pediatric population PK model of isavuconazole, the active moiety of isavuconazonium sulfate.

Conditions

  • Hematological Malignancy

Interventions

  • isavuconazonium sulfate - intravenousDrug

    IV infusion

  • isavuconazonium sulfate - oralDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of isavuconazole in plasma: Cmax at steady stateTime frame: Up to 7 days
  2. PK of isavuconazole in plasma: AUCtauTime frame: Up to 7 days
  3. PK of isavuconazole in plasma: tmaxTime frame: Up to 7 days
  4. PK of isavuconazole in plasma: CtroughTime frame: Up to 28 days
  5. PK of isavuconazole in plasma: CLTime frame: Up to 28 days
  6. PK of isavuconazole in plasma: VssTime frame: Up to 28 days
  7. PK of isavuconazole in plasma: AUCssTime frame: Up to 28 days
  8. PK of isavuconazole in plasma: t 1/2Time frame: Up to 28 days
  9. Safety assessed by nature, frequency and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 58 days
  10. Number of patients with vital sign abnormalities and/or adverse eventsTime frame: Up to 28 days
  11. Number of patients with laboratory value abnormalities and/or adverse eventsTime frame: Up to 28 days
  12. Safety assessed by routine 12- lead electrocardiogram (ECG)Time frame: Up to 28 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Miller Children's Hospital

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • CHOC Children's Hospital of Orange County

    Orange, California

  • Nicklaus Children's Hospital

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Louisville

    Louisville, Kentucky

  • Children's Hospitals and Clinics of Minnesota

    Minneapolis, Minnesota

  • Children's Mercy Kansas City

    Kansas City, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • University Hospital of Cleveland

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • The Children's Hospital at TriStar Centennial Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Texas Children's Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.